Table 2.

Unsolicited Treatment-Related Adverse Events (Exposed Set ^a )

	Placebo (n = 30)b	mRNA-1653							Combined (n = 94)b
		25 μg	75 μg		150 μg		300 μg
		2-Dose (n = 4)b	1-Dose (n = 13)b	2-Dose (n = 17)b	1-Dose (n = 13)b	2-Dose (n = 17)b	1-Dose (n = 13)b	2-Dose (n = 17)b
No. (%)c
All unsolicited AEs	0	0	0	1 (5.9)	1 (7.7)	3 (17.6)	3 (23.1)	3 (17.6)	11 (11.7)
SAEs	0	0	0	0	0	0	0	0	0
Fatal AEs	0	0	0	0	0	0	0	0	0
AEs leading to withdrawal	0	0	0	0	0	0	0	0	0
AEs grade 3+	0	0	0	0	0	0	1 (7.7)	2 (11.8)	3 (3.2)
AESIs	0	0	0	0	0	0	0	0	0
MAEs	0	0	0	0	0	0	2 (15.4)	3 (17.6)	5 (5.3)

Abbreviations: AE, adverse event; AESI, adverse event of special interest; MAE, medically attended adverse event; SAE, serious adverse event.

^aAll participants in the randomized set who received any study vaccination.

^bNumber of participants randomized and exposed to study vaccination.

^cNumber of participants in each treatment group reporting the event.